| 000 | 01694 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516042950.0 | ||
| 264 | 0 | _c20110926 | |
| 008 | 201109s 0 0 eng d | ||
| 022 | _a1095-6859 | ||
| 024 | 7 |
_a10.1016/j.ygyno.2011.05.040 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSantin, Alessandro D | |
| 245 | 0 | 0 |
_aPhase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. _h[electronic resource] |
| 260 |
_bGynecologic oncology _cSep 2011 |
||
| 300 |
_a495-500 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 | _aCetuximab |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aUterine Cervical Neoplasms _xdrug therapy |
| 700 | 1 | _aSill, Michael W | |
| 700 | 1 | _aMcMeekin, D Scott | |
| 700 | 1 | _aLeitao, Mario M | |
| 700 | 1 | _aBrown, Jubilee | |
| 700 | 1 | _aSutton, Gregory P | |
| 700 | 1 | _aVan Le, Linda | |
| 700 | 1 | _aGriffin, Patricia | |
| 700 | 1 | _aBoardman, Cecelia H | |
| 773 | 0 |
_tGynecologic oncology _gvol. 122 _gno. 3 _gp. 495-500 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ygyno.2011.05.040 _zAvailable from publisher's website |
| 999 |
_c20939043 _d20939043 |
||